# Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

> **NCT06915870** · NA · COMPLETED · sponsor: **Fatima Maqsood** · enrollment: 108 (actual)

## Conditions studied

- Diabetes Mellitus
- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin 10 mg daily
- **DRUG:** Empagliflozin 10 MG OD

## Key facts

- **NCT ID:** NCT06915870
- **Lead sponsor:** Fatima Maqsood
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-12
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06915870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06915870, "Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06915870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*